| Literature DB >> 30911407 |
Charlotte Brandt Sørensen1,2, Vicente Andrés3,4, Beatriz Dorado3,4, Gro Grunnet Pløen1,2, Ana Barettino3,4, Alvaro Macías3, Pilar Gonzalo3,4, María Jesús Andrés-Manzano3,4, Cristina González-Gómez3,4, Carlos Galán-Arriola3,4, José Manuel Alfonso3, Manuel Lobo3,4, Gonzalo J López-Martín3, Antonio Molina3, Raúl Sánchez-Sánchez5, Joaquín Gadea6, Javier Sánchez-González7, Ying Liu8, Henrik Callesen8, David Filgueiras-Rama3,4,9, Borja Ibáñez3,4,10.
Abstract
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare genetic disorder for which no cure exists. The disease is characterized by premature aging and inevitable death in adolescence due to cardiovascular complications. Most HGPS patients carry a heterozygous de novo LMNA c.1824C > T mutation, which provokes the expression of a dominant-negative mutant protein called progerin. Therapies proven effective in HGPS-like mouse models have yielded only modest benefit in HGPS clinical trials. To overcome the gap between HGPS mouse models and patients, we have generated by CRISPR-Cas9 gene editing the first large animal model for HGPS, a knockin heterozygous LMNA c.1824C > T Yucatan minipig. Like HGPS patients, HGPS minipigs endogenously co-express progerin and normal lamin A/C, and exhibit severe growth retardation, lipodystrophy, skin and bone alterations, cardiovascular disease, and die around puberty. Remarkably, the HGPS minipigs recapitulate critical cardiovascular alterations seen in patients, such as left ventricular diastolic dysfunction, altered cardiac electrical activity, and loss of vascular smooth muscle cells. Our analysis also revealed reduced myocardial perfusion due to microvascular damage and myocardial interstitial fibrosis, previously undescribed readouts potentially useful for monitoring disease progression in patients. The HGPS minipigs provide an appropriate preclinical model in which to test human-size interventional devices and optimize candidate therapies before advancing to clinical trials, thus accelerating the development of effective applications for HGPS patients.Entities:
Year: 2019 PMID: 30911407 PMCID: PMC6423020 DOI: 10.1038/s41421-019-0084-z
Source DB: PubMed Journal: Cell Discov ISSN: 2056-5968 Impact factor: 10.849
Fig. 1Knockin heterozygous LMNA c.1824C > T Yucatan minipigs exhibit HGPS-like external phenotype, growth retardation, and premature death.
a Genetic engineering procedure for generating Hutchinson-Gilford progeria syndrome (HGPS) knockin Yucatan minipig fibroblasts by CRISPR/Cas9-mediated homologous recombination. The area of hybridization for sgRNA1 in genomic DNA is indicated by a yellow arrowhead, the area of recombination between genomic DNA and donor DNA template is indicated by green lines, and the single C > T base mutation in the donor DNA template is indicated by a red T in exon 11. LHA and RHA respectively indicate the left and right homology arms surrounding the C > T mutation (not drawn to scale). For an overview of the whole method to generate HGPS minipigs and its efficiency see Supplementary Fig. S2. For detailed information of molecular tools see Supplementary Table S1 and 2. b Genomic LMNA exon 11 sequence of wild-type (WT) minipig fibroblasts and the generated heterozygous HGPS knockin fibroblast clone. Note that WT cells are homozygous for the C nucleotide in position c.1824 (blue arrowhead), and HGPS cells harbor both the WT C allele and the mutant T allele (red arrowhead). c Representative photographs showing the normal appearance of HGPS minipigs at birth and the severe premature-aging external phenotype at 5.5–6 months of age. Note that pictures were not taken at the same distance. See also Supplementary Fig. S3 and Movies S1-5. d HGPS Yucatan minipigs experience difficulty to thrive. The graph shows body weight/age curves (n = 6 WT; n = 10 HGPS). e HGPS minipigs die prematurely. Green dots in the Kaplan-Meier survival curve are censored data (1 HGPS minipig died during anesthesia induction in preparation for imaging tests and another was euthanized due to humane end-point criteria)
Fig. 2Progerin expression in Hutchinson-Gilford progeria syndrome (HGPS) minipigs.
a Design of primers for PCR amplification of progerin mRNA. F forward primer, R reverse primer (which spans from progerin exon 12 to the 3′ end of exon 11 across the in-frame 150-nucleotide deletion produced by the alternative splicing caused by the LMNA c.1824C > T mutation). b Representative agarose gels showing PCR detection of progerin mRNA in wild-type (WT) and HGPS minipig tissues (each lane corresponds to a different pig). Skin fibroblasts from HGPS patients and healthy controls were used as positive and negative controls, respectively. First lane, DNA ladder. c Comparison of the C-terminal amino-acid sequences of human progerin and HGPS minipig progerin, which was predicted with ExPASy software from the DNA sequence of the gel-purified 482-bp PCR product specific to HGPS pigs (cf. b). d Representative immunoblots for lamin A/C and progerin protein in WT and HGPS minipig heart and aorta (heart: 60 µg protein/lane, aorta: 30 µg protein/lane; each lane corresponds to a different pig). Fibroblasts from WT and HGPS mice (Lmna) were used as progerin expression-negative and -positive controls, respectively. GADPH was used as loading control
Fig. 3Heart microvascular dysfunction and fibrosis in Hutchinson-Gilford progeria syndrome (HGPS) minipigs.
a Left ventricular (LV) fibrosis in HGPS minipigs revealed by delayed gadolinium enhancement magnetic resonance imaging (MRI). Representative images are shown. Red arrowheads indicate the area of contrast deposition. b LV microvascular damage in HGPS minipigs determined by cardiac MRI-determined absolute quantitative perfusion after gadolinium administration (n = 6 WT and n = 7 HGPS minipigs, 4.3–5.5 months old). The images show representative examples of LV flow with perfusion ranging from 50 (red) to 200 (yellow) ml/min/100 g. Arrowheads indicate the non-perfused area. c Collagen deposition in LV and septal coronary arteries of WT and HGPS hearts. Images show representative Masson trichrome (MT) staining of heart cross sections, revealing increased collagen deposition (green/blue staining) in HGPS hearts. Left and center graphs: mean percentage collagen content in medial and adventitial layers of arterioles >65 μm in diameter, quantified by image deconvolution (area analyzed, 170 mm2 in LV and 120 mm2 in septum). Right graph: adventitial hyperthrophy quantified as the ratio of adventitial to medial perimeter (11–27 arterioles of mean diameter >50 μm per minipig in LV or septum). d Smooth muscle cell loss in the medial layer of LV and septum arterioles in HGPS minipigs. Representative immunofluorescence images show staining for α-smooth muscle actin (SMA) in red, CD31 (endothelial cell marker) in green, and nuclei in blue. The graph shows mean percentage SMA signals in the medial layer of 12–41 arterioles per minipig in LV or septum. See also Supplementary Fig. S4. e Representative images of MT staining in heart cross sections, showing myocardial fibrosis in HGPS minipigs. Black arrows indicate areas of intense MT staining. Images were deconvoluted to quantify mean percentage myocardial fibrosis in vessel-free myocardial areas (seven areas in LV and six areas in septum; 470 μm2 each region analyzed)
Fig. 4Systolic and diastolic dysfunction in Hutchinson-Gilford progeria syndrome (HGPS) minipigs.
Cardiac magnetic resonance imaging (MRI) and echocardiography analysis of HGPS minipigs (n = 7–8) and wild-type (WT) minipigs (n = 5–6) of a similar age (~4.3–5.5 months) revealed enlarged left atria (LA) and increased left ventricular (LV) filling pressures, as well as systolic and diastolic LV dysfunction in HGPS minipigs. a MRI measurements of LV ejection fraction (LVEF). Representative four chamber long axis views are shown on the left. b Echocardiographic measurements of mitral early wave deceleration time (shown in yellow numbers in the representative images on the left). c Echocardiographic measurements of LA size (shown in yellow numbers in the representative images on the left. See also unaffected systolic and diastolic parameters in HGPS minipigs in Supplementary Fig. S5
Fig. 5Electrocardiographic (ECG) alterations and aberrant connexin 43 (Cnx43) localization in the hearts of Hutchinson-Gilford progeria syndrome (HGPS) minipigs.
a Representative ECG traces recorded in wild-type (WT) and HGPS minipigs. b HGPS minipigs show bradycardia and QRS complex prolongation on ECG. For each parameter, a set of 10 beats per animal was analyzed and the mean was represented. c Cnx43 is mislocalized in the plasma membrane of HGPS cardiomyocytes. Representative immunofluorescence images of heart tissue show staining for Cnx43 (green), N-Cadh (red), and nuclei (blue). The graph shows the percentage of N-Cadh/Cnx43 co-localization based on the mean of three 236 µm2 areas per heart tissue sample
Fig. 6Severe pre-mortem cardiac conduction abnormalities in Hutchinson-Gilford progeria syndrome (HGPS) minipigs.
a An implantable loop recorder used for continuous electrocardiography (ECG) monitoring after subcutaneous implantation in wild-type (WT) and HGPS minipigs. b Representative single-lead ECG trace from a WT minipig. c ECG trace from a HGPS minipig, showing a wide QRS complex and short-duration polymorphic ventricular tachycardia before complete atrio-ventricular block at the moment of death. d ECG trace from a HGPS minipig, showing ST-segment elevation immediately before complete atrio-ventricular block at the moment of death. Red arrows in b–d indicate the P waves on the surface ECG; blue asterisks indicate the QRS complex. Traces correspond to a standard sweep speed of 25 mm/s and standard amplitude calibration of 10 mm/mV